Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Regen BioPharma Inc entered into Purchase Agreement with Coventry Enterprises, LLC valued at $175,000 (effective 2023-09-12).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Coventry Enterprises, LLC
- Value
- $175,000
- Effective
- 2023-09-12
Exact text from the filing
Effective September 12, 2023 Regen Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Coventry Enterprises, LLC (“Coventry”), pursuant to which Coventry Enterprises purchased a 10% unsecured promissory Note (the “Note”) from the Company in the principal amount of $175,000
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Regen BioPharma Inc entered into Registration Rights Agreement with Coventry (effective 2023-09-12).
- Action
- entry
- Counterparty
- Coventry
- Effective
- 2023-09-12
Exact text from the filing
In connection with the Equity Line Agreement the Company also entered into a Registration Rights Agreement, dated September 12, 2023 with Coventry (the “Registration Rights Agreement”), pursuant to which the Company agreed to register for resale under the Securities Act of 1933 shares issuable in accordance with the Equity Line Agreement
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Regen BioPharma Inc entered into common stock purchase agreement with Coventry valued at up to Ten Million Dollars ($10,000,000) (effective 2023-09-12).
- Action
- entry
- Agreement
- atm program
- Counterparty
- Coventry
- Value
- up to Ten Million Dollars ($10,000,000)
- Effective
- 2023-09-12
Exact text from the filing
On September 12, 2023 the Company entered into a common stock purchase agreement (the “Equity Line Agreement”) with Coventry providing for an equity financing facility (the “Equity Line”).
View on SEC.gov